Clinical trial
Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors
NCT00187174 · St. Jude Children's Research Hospital, Other · Completed
Key facts
| NCT number | NCT00187174 |
|---|---|
| Title | Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors |
| Official title | Phase I Trial of RAD001C (Everolimus) in Pediatric Patients With Recurrent Refractory Solid Tumors or Brain Tumors |
| Lead sponsor | St. Jude Children's Research Hospital, Other |
| Collaborators | Novartis Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Tumors, Brain Tumors, Rhabdomyosarcoma, Sarcoma, Soft Tissue |
| Intervention type | Drug |
| Interventions | Everolimus |
| Enrollment | 41 |
| Start date | Oct 1, 2004 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Sep 16, 2005 |
| Last update posted | Mar 4, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: